Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

oral myeloma therapy

- PMLiVE

NICE set to reject wider use of Eisai’s Halaven

Issues draft guidance recommending against second-line use in breast cancer

- PMLiVE

MHRA joins Instagram as part of Yellow Card drive

UK medicines regulator follows in the footsteps of NICE in using the channel

- PMLiVE

EMA forges closer ties with HTA umbrella group

Agrees joint work plan with the European Network for Health Technology Assessment

- PMLiVE

Takeda Italia takes home digital innovation prize at Le Fonti Awards 2017

The pharmaceutical company wins award for its MyHospitalHub project

- PMLiVE

Amsterdam picked to host the European Medicines Agency

But regulator faces a “challenging” relocation project to depart from London

National Institute for Health and Care Excellence NICE logo

NICE backs two advanced breast cancer drugs after price cuts

An estimated 8,000 women will be eligible to receive the drugs due to discounts

dengue fever mosquito

Takeda dengue vaccine data looks good as it chases Sanofi

TAK-003 achieved a 71% reduction in developing the virus compared to placebo

- PMLiVE

Merck pulls Keytruda filing in Europe, despite US approval

Phase II KeyNote-0241 trial results failed to win over the EMA

- PMLiVE

Moving times

Continuity and stability are vital when it comes to the EMA's relocation when it leaves London

- PMLiVE

NICE backs Pfizer’s Xeljanz for RA

But UK’s cost-effectiveness watchdog removes two drugs from CDF

- PMLiVE

SMC backtracks on Janssen’s multiple myeloma treatment Darzalex

Will now recommend the first-in-class treatment after securing a discount

- PMLiVE

EMA sets aside £32m for temporary staff to help with Brexit move

As agency warns current tender system needs to be updated

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links